Bio-Rad Laboratories (BIO) reported Q1 adjusted earnings late Thursday of $2.54 per diluted share, up from $2.30 a year earlier.
Analysts polled by FactSet expected $1.81.
Revenue for the quarter ended March 31 was $585.4 million, compared with $610.8 million a year earlier.
Analysts surveyed by FactSet expected $573.3 million.
The company said it now expects 2025 non-GAAP, currency-neutral revenue to range from a decline of 1% to growth of 1.5%, compared with its prior revenue growth estimate of about 1.5% to 3.5%.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。